Milestone Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Clinical and Corporate Update

/PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative...

Related Keywords

China ,Ji Xing ,Jilin ,Montreal ,Quebec ,Canada ,Japan ,United States ,Japanese ,Americans ,David Pitts ,Joseph Oliveto ,Bruce Stambler ,Sean Pokorney ,Duke University School Of Medicine ,Ji Xing Pharmaceuticals Limited ,Nasdaq ,Arrhythmia Core Laboratory ,Company Remains On Track To Report ,Milestone Pharmaceuticals Inc ,Centers For Disease ,Us Securities Exchange Commission ,Arrhythmia Research ,Heart Rhythm Society ,American College Of Cardiology ,Piedmont Heart Institute ,Ji Xing Pharmaceuticals ,Drug Administration ,Duke Clinical Research Institute ,Exchange Commission ,Milestone Pharmaceuticals ,Chief Executive Officer ,Required Number ,Double Blind Study Medication ,Initiate Preparation ,Primary Efficacy Analysis ,Company Remains ,Mid Second Half ,New Drug Application ,United States Food ,Enrolled First Patient ,Label Extension Study ,Heart Rhythm ,Key Opinion Leader ,Cardiac Arrhythmia Research ,Assistant Professor ,Duke University School ,Clinical Analysis Evaluating ,Drug Characteristics ,Etripamil Presented ,American College ,Annual Scientific Session ,License Agreement ,Atrial Fibrillation ,Rapid Ventricular ,Disease Control ,Private Securities Litigation Reform Act ,